Toggle light / dark theme

Jaeb Center for Health Research conducted a randomized controlled trial evaluating the impact of automated insulin delivery (AID) in adults with insulin-treated type 2 diabetes. AID significantly lowered glycated hemoglobin (HbA1c) levels and improved glucose control compared to standard insulin therapy with continuous glucose monitoring (CGM).

AID therapy resulted in a mean HbA1c reduction of 0.9 percentage points over 13 weeks, while the control group experienced a 0.3 percentage point reduction.

Automated systems have demonstrated benefits for patients with type 1 diabetes, yet their efficacy and safety for individuals with type 2 diabetes remain less established. Prior studies have either lacked randomized controlled designs or involved limited sample sizes, creating a gap in clinical understanding.

Scientists have developed shape-shifting nanorobots that can flow like liquid and solidify like steel, paving the way for breakthroughs in medicine, engineering, and robotics. These nanobots, inspired by gallium-based materials, respond to magnetic fields, allowing them to navigate through tight spaces, repair electronics, and even perform medical procedures. While still in the early stages, this futuristic technology could lead to self-healing materials, autonomous repairs, and shape-adaptive robotics, bringing us closer to a world of smart, responsive materials.

Generative artificial intelligence (AI) systems can be optimized using TextGrad, a framework that performs optimization by backpropagating large-language-model-generated feedback; TextGrad enables optimization across diverse tasks, including radiotherapy treatment plans and molecule generation.

A little over a year ago, Joseph Coates was told there was only one thing left to decide. Did he want to die at home, or in the hospital?

Coates, then 37 and living in Renton, Wash., was barely conscious. For months, he had been battling a rare blood disorder called POEMS syndrome, which had left him with numb hands and feet, an enlarged heart and failing kidneys. Every few days, doctors needed to drain liters of fluid from his abdomen. He became too sick to receive a stem cell transplant — one of the only treatments that could have put him into remission.

“I gave up,” he said. “I just thought the end was inevitable.”

But Coates’s girlfriend, Tara Theobald, wasn’t ready to quit. So she sent an email begging for help to a doctor in Philadelphia named David Fajgenbaum, whom the couple met a year earlier at a rare disease summit.


Scientists are using machine learning to find new treatments among thousands of old medicines.

In today’s column, I debunk the common myth that if we attain artificial general intelligence (AGI) the resultant AI will be a solo colossus or said-to-be “one big brain”

Let’s talk about it.

This analysis of an innovative AI breakthrough is part of my ongoing Forbes column coverage on the latest in AI, including identifying and explaining various impactful AI complexities (see the link here).

In a study on ovarian cancer cells, researchers from Karolinska Institutet demonstrate how the tumor environment influences how cancer cells respond to drugs by using AI. The study has been published in the journal Communications Biology.

The cancer cells were cultured together with fibroblasts, a type of support cell, and treated with different drugs. Advanced computer programs were used to analyze images of the cancer cells to see how they changed. Fibroblasts play an important role in the . They can promote , spread, and , as well as affect the .

“Our study shows that cultured together with fibroblasts change their appearance when treated with drugs. This demonstrates how the tumor environment influences how cancer cells respond to drugs,” says Osheen Sharma, Ph.D. student at the Department of Oncology-Pathology, Karolinska Institutet, and the study’s first author.

A new neuroimaging study has revealed that viewing nature can help ease how people experience pain, by reducing the brain activity linked to pain perception.

Published in the journal Nature Communications, the research offers a promising foundation for new types of non-pharmacological pain treatments.

Using an fMRI scanner, researchers monitored the brain activity of 49 participants in Austria, as they received pain delivered through a series of small electric shocks. When they were watching videos of a natural scene compared to a city or an indoor office, participants not only reported feeling less pain, but scans showed the specific brain responses associated with processing pain changed too.

The study used advanced machine-learning to analyse the brain networks related to pain processing. The team discovered that the raw sensory signals the brain receives when something hurts were reduced when watching a carefully designed, high quality, virtual nature scene. The study confirmed previous findings that suggest nature can reduce subjective reports of pain, and also marks the first clear demonstration of how natural environments influence the brain, helping to buffer against unpleasant experiences.

Neura Robotics has built a diverse portfolio of robots, including MAiRA, the world’s first cognitive cobot. MAiRA uses artificial intelligence for autonomous operation and safe human interaction. The company also offers the MAV, a mobile robot for heavy load transport, and MiPA, a humanoid robot designed for tasks like serving trays in hospitals.

Through its cloud-based Neuraverse platform, Neura also creates cutting-edge software, in contrast to many robotics companies that only concentrate on hardware. Known as an “ecosystem for cognitive robotics,” the Neuraverse is a marketplace for robotic abilities and an operating system designed to spur innovation.

Many businesses displayed humanoid robots at CES 2025, demonstrating the momentum of the robotics sector. The humanoid robot “Melody,” created by Realbotix, is simple to assemble and disassemble. In the meantime, the full-size bipedal humanoid robot known as the “CASBOT 01” was introduced by China’s Lingbao CASBOT.

A group of Carnegie Mellon University researchers recently devised a method allowing them to create large amounts of a material required to make two-dimensional (2D) semiconductors with record high performance. Their paper, published in ACS Applied Materials & Interfaces in late December 2024, could lead to more efficient and tunable photodetectors, paving the way for the next generation of light-sensing and multifunctional optoelectronic devices.

“Semiconductors are the key enabling technology for today’s electronics, from laptops to smartphones to AI applications,” said Xu Zhang, assistant professor of electrical and computer engineering. “They control the flow of electricity, acting as a bridge between conductors (which allow electricity to flow freely) and insulators (which block it).”

Zhang’s research group wanted to develop a certain kind of photodetector, a device capable of detecting light and which can be used in a variety of applications. To create this photodetector, the group needed to use materials that were an atom’s-width thick, or as close to 2D as is possible.